SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $47,061.84 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $7.63, for a total transaction of $47,061.84. Following the completion of the transaction, the insider owned 338,884 shares of the company’s stock, valued at approximately $2,585,684.92. This trade represents a 1.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $7.97 on Thursday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 52 week low of $3.15 and a 52 week high of $8.98. The stock’s 50-day moving average price is $7.18 and its 200-day moving average price is $5.76. The stock has a market capitalization of $668.60 million, a PE ratio of -6.93 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research increased their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently bought and sold shares of the business. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. Royal Bank of Canada increased its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the period. AXQ Capital LP acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at $119,000. Silverberg Bernstein Capital Management LLC raised its holdings in SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after purchasing an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $567,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.